Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn

Table of Contents

February 01, 2006; Volume 34,Issue 2

Short Communications

  • You have access
    GLUCURONIDATION OF THE ASPIRIN METABOLITE SALICYLIC ACID BY EXPRESSED UDP-GLUCURONOSYLTRANSFERASES AND HUMAN LIVER MICROSOMES
    Gwendolyn E. Kuehl, Jeannette Bigler, John D. Potter and Johanna W. Lampe
    Drug Metabolism and Disposition February 2006, 34 (2) 199-202; DOI: https://doi.org/10.1124/dmd.105.005652
  • You have access
    EVALUATION OF INHIBITORY POTENCIES FOR COMPOUNDS INHIBITING P-GLYCOPROTEIN BUT WITHOUT MAXIMUM EFFECTS: F2 VALUES
    Johanna Weiss and Walter Emil Haefeli
    Drug Metabolism and Disposition February 2006, 34 (2) 203-207; DOI: https://doi.org/10.1124/dmd.105.007377
  • You have access
    ESTIMATION OF ALDEHYDE OXIDASE ACTIVITY IN VIVO FROM CONVERSION RATIO OF N1-METHYLNICOTINAMIDE TO PYRIDONES, AND INTRASPECIES VARIATION OF THE ENZYME ACTIVITY IN RATS
    Kazumi Sugihara, Yoshitaka Tayama, Kazuhiro Shimomiya, Daisuke Yoshimoto, Shigeru Ohta and Shigeyuki Kitamura
    Drug Metabolism and Disposition February 2006, 34 (2) 208-212; DOI: https://doi.org/10.1124/dmd.105.006544

Articles

  • You have access
    IN VIVO METABOLISM OF [14C]RUBOXISTAURIN IN DOGS, MICE, AND RATS FOLLOWING ORAL ADMINISTRATION AND THE STRUCTURE DETERMINATION OF ITS METABOLITES BY LIQUID CHROMATOGRAPHY/MASS SPECTROMETRY AND NMR SPECTROSCOPY
    Robert J. Barbuch, Kristina Campanale, Chad E. Hadden, Milton Zmijewski, Ping Yi, Douglas D. O'Bannon, Jennifer L. Burkey and Palaniappan Kulanthaivel
    Drug Metabolism and Disposition February 2006, 34 (2) 213-224; DOI: https://doi.org/10.1124/dmd.105.007401
  • You have access
    METABOLISM OF MOMETASONE FUROATE AND BIOLOGICAL ACTIVITY OF THE METABOLITES
    S. Sahasranaman, M. Issar and G. Hochhaus
    Drug Metabolism and Disposition February 2006, 34 (2) 225-233; DOI: https://doi.org/10.1124/dmd.105.005702
  • You have access
    DISTINCT ROLE OF BILOBALIDE AND GINKGOLIDE A IN THE MODULATION OF RAT CYP2B1 AND CYP3A23 GENE EXPRESSION BY GINKGO BILOBA EXTRACT IN CULTURED HEPATOCYTES
    Thomas K. H. Chang, Jie Chen and Xiao Wei Teng
    Drug Metabolism and Disposition February 2006, 34 (2) 234-242; DOI: https://doi.org/10.1124/dmd.105.005751
  • You have access
    CHARACTERIZATION OF THE IN VITRO METABOLISM OF SELECTIVE ANDROGEN RECEPTOR MODULATOR USING HUMAN, RAT, AND DOG LIVER ENZYME PREPARATIONS
    Wenqing Gao, Zengru Wu, Casey E. Bohl, Jun Yang, Duane D. Miller and James T. Dalton
    Drug Metabolism and Disposition February 2006, 34 (2) 243-253; DOI: https://doi.org/10.1124/dmd.105.007112
  • You have access
    INTERSPECIES DIFFERENCES IN PHARMACOKINETICS AND METABOLISM OF S-3-(4-ACETYLAMINO-PHENOXY)-2-HYDROXY-2-METHYL-N-(4-NITRO-3-TRIFLUOROMETHYLPHENYL)-PROPIONAMIDE: THE ROLE OF N-ACETYLTRANSFERASE
    Wenqing Gao, Jeffrey S. Johnston, Duane D. Miller and James T. Dalton
    Drug Metabolism and Disposition February 2006, 34 (2) 254-260; DOI: https://doi.org/10.1124/dmd.105.007120
  • You have access
    ROLE OF MRP2 IN THE HEPATIC DISPOSITION OF MYCOPHENOLIC ACID AND ITS GLUCURONIDE METABOLITES: EFFECT OF CYCLOSPORINE
    Ian S. Westley, Leonie R. Brogan, Raymond G. Morris, Allan M. Evans and Benedetta C. Sallustio
    Drug Metabolism and Disposition February 2006, 34 (2) 261-266; DOI: https://doi.org/10.1124/dmd.105.006122
  • You have access
    STRUCTURAL ELUCIDATION OF HUMAN OXIDATIVE METABOLITES OF MURAGLITAZAR: USE OF MICROBIAL BIOREACTORS IN THE BIOSYNTHESIS OF METABOLITE STANDARDS
    Donglu Zhang, Haiying Zhang, Nelly Aranibar, Ronald Hanson, Yande Huang, Peter T. Cheng, Shung Wu, Samuel Bonacorsi, Mingshe Zhu, Arun Swaminathan and W. Griffith Humphreys
    Drug Metabolism and Disposition February 2006, 34 (2) 267-280; DOI: https://doi.org/10.1124/dmd.105.007153
  • You have access
    METABOLISM OF THE PSYCHOTOMIMETIC TRYPTAMINE DERIVATIVE 5-METHOXY-N,N-DIISOPROPYLTRYPTAMINE IN HUMANS: IDENTIFICATION AND QUANTIFICATION OF ITS URINARY METABOLITES
    Tooru Kamata, Munehiro Katagi, Hiroe T. Kamata, Akihiro Miki, Noriaki Shima, Kei Zaitsu, Mayumi Nishikawa, Einosuke Tanaka, Katsuya Honda and Hitoshi Tsuchihashi
    Drug Metabolism and Disposition February 2006, 34 (2) 281-287; DOI: https://doi.org/10.1124/dmd.105.005835
  • You have access
    BRAIN CYCLOSPORIN A LEVELS ARE DETERMINED BY ONTOGENIC REGULATION OF MDR1A EXPRESSION
    Kerry B. Goralski, Philip D. Acott, Albert D. Fraser, David Worth and Christopher J. Sinal
    Drug Metabolism and Disposition February 2006, 34 (2) 288-295; DOI: https://doi.org/10.1124/dmd.105.007427
  • You have access
    INHIBITION OF LUNG CANCER CELL GROWTH BY QUERCETIN GLUCURONIDES VIA G2/M ARREST AND INDUCTION OF APOPTOSIS
    Jen-Hung Yang, Te-Chun Hsia, Hsiu-Maan Kuo, Pei-Dawn Lee Chao, Chi-Chung Chou, Yau-Huei Wei and Jing-Gung Chung
    Drug Metabolism and Disposition February 2006, 34 (2) 296-304; DOI: https://doi.org/10.1124/dmd.105.005280
  • You have access
    DEMONSTRATION OF DOCOSAHEXAENOIC ACID AS A BIOAVAILABILITY ENHANCER FOR CYP3A SUBSTRATES: IN VITRO AND IN VIVO EVIDENCE USING CYCLOSPORIN IN RATS
    Vilasinee Hirunpanich, Jun Katagi, Benjabhorn Sethabouppha and Hitoshi Sato
    Drug Metabolism and Disposition February 2006, 34 (2) 305-310; DOI: https://doi.org/10.1124/dmd.105.007088
  • You have access
    INEFFICIENT REPAIR OF TAMOXIFEN-DNA ADDUCTS IN RATS AND MICE
    Sung Yeon Kim, Naomi Suzuki, Y. R. Santosh Laxmi and Shinya Shibutani
    Drug Metabolism and Disposition February 2006, 34 (2) 311-317; DOI: https://doi.org/10.1124/dmd.105.007013
  • You have access
    BRAIN DISTRIBUTION OF CETIRIZINE ENANTIOMERS: COMPARISON OF THREE DIFFERENT TISSUE-TO-PLASMA PARTITION COEFFICIENTS: Kp, Kp,u, AND Kp,uu
    Anubha Gupta, Pierre Chatelain, Roy Massingham, E. Niclas Jonsson and Margareta Hammarlund-Udenaes
    Drug Metabolism and Disposition February 2006, 34 (2) 318-323; DOI: https://doi.org/10.1124/dmd.105.007211
  • You have access
    DEVELOPMENT OF NOVEL FURANOCOUMARIN DIMERS AS POTENT AND SELECTIVE INHIBITORS OF CYP3A4
    E. Row, S. A. Brown, A. V. Stachulski and M. S. Lennard
    Drug Metabolism and Disposition February 2006, 34 (2) 324-330; DOI: https://doi.org/10.1124/dmd.105.007294
  • You have access
    DISTRIBUTION OF (7α)-21-[4-[(DIETHYLAMINO) METHYL]-2-METHOXYPHENOXY]-7-METHYL-19-NORPREGNA-1,3,5(10)-TRIEN-3-OL-20-[14C]2-HYDROXY-1,2,3-PROPANETRICARBOXYLATE ([14C]TAS-108) AND ITS METABOLITES AFTER SINGLE ORAL ADMINISTRATION TO RATS BEARING 7,12-DIMETHYLBENZ(α)ANTHRACENE-INDUCED MAMMARY TUMOR
    Hidetoshi Yamaya, Mayuko Saeki, Ken-ichiro Yoshida, Jiro Shibata, Shingo Yano, Yoshiaki Sato, Atsushi Takao, Takashi Shindo, Aman U. Buzdar and Sekio Nagayama
    Drug Metabolism and Disposition February 2006, 34 (2) 331-338; DOI: https://doi.org/10.1124/dmd.105.005504
Back to top
PreviousNext

In this issue

Drug Metabolism and Disposition: 34 (2)
Drug Metabolism and Disposition
Vol. 34, Issue 2
1 Feb 2006
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)
Sign up for alerts

Jump to

  • Short Communications
  • Articles
  • Most Cited
  • Most Read
Loading
  • Cytochrome P450 inhibitors. Evaluation of specificities in the in vitrometabolism of therapeutic agents by human liver microsomes.
  • Prediction of Human Clearance of Twenty-Nine Drugs from Hepatic Microsomal Intrinsic Clearance Data: An Examination of In Vitro Half-Life Approach and Nonspecific Binding to Microsomes
  • DRUG-DRUG INTERACTIONS FOR UDP-GLUCURONOSYLTRANSFERASE SUBSTRATES: A PHARMACOKINETIC EXPLANATION FOR TYPICALLY OBSERVED LOW EXPOSURE (AUCI/AUC) RATIOS
  • In Vitro-In Vivo Scaling of CYP Kinetic Data Not Consistent with the Classical Michaelis-Menten Model
  • THE HUMAN INTESTINAL CYTOCHROME P450 “PIE”
More...
Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics